Normalization of Cerebral Blood Flow, Neurochemicals, and White Matter Integrity After Kidney Transplantation

Rebecca J. Lepping^{1,2}, Robert N. Montgomery³, Palash Sharma³, Jonathan D. Mahnken^{2,3}, Eric D. Vidoni^{2,4}, In-Young Choi^{1,4}, Mark J. Sarnak⁶, William M. Brooks^{1,2,4}, Jeffrey M. Burns^{2,4}, Aditi Gupta^{2,5}

Affiliations: ¹Hoglund Biomedical Imaging Center, ²University of Kansas Alzheimer's Disease Center, ³Department of Biostatistics & Data Science, ⁴Department of Neurology, and ⁵Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS and ⁶Division of Nephrology and Hypertension, Department of Internal Medicine, Tufts Medical Center, Boston, MA

Running title: Brain changes with kidney transplant

Abstract word count: 249

Text word count: 2717 (not including methods).

Corresponding author:

Aditi Gupta, M.D.

Division of Nephrology and Hypertension

Department of Medicine

University of Kansas Medical Center

3901 Rainbow Blvd

Kansas City, KS 66160

Email: agupta@kumc.edu

Key words: ESKD, kidney transplantation, cerebral blood flow, neurochemicals, white matter integrity, ASL, MRSI, DTI

Significance statement: Kidney disease is accompanied by brain structural and physiological abnormalities and increased risk of dementia and stroke. Renal replacement therapy with dialysis does not normalize these brain abnormalities. We evaluated these brain abnormalities before and after kidney transplantation and demonstrated that unlike dialysis, kidney transplantation normalizes cerebral blood flow, neurochemical concentrations and white matter integrity. These changes persist beyond initial post-transplantation period and thus cannot be attributed to peri-procedural interventions like steroids. These results indicate reversibility of brain abnormalities in kidney disease. Further studies are needed to understand the mechanisms underlying these abnormalities and explore interventions for prevention and mitigation in patients who cannot be transplanted.

Abstract:

Background: Chronic kidney disease (CKD) is associated with abnormalities in cerebral blood flow (CBF), cerebral neurochemical concentrations and white matter integrity, each of which are associated with adverse clinical consequences in the non-CKD population, and may explain the high prevalence of dementia and stroke in end stage kidney disease (ESKD). Since cognition improves after kidney transplantation (KT), we examined these brain abnormalities pre-to post-KT to identify potential reversibility in ESKD-associated brain abnormalities.

Methods: We measured the effects of KT on CBF assessed by arterial spin labeling, cerebral neurochemical concentrations (N-acetylaspartate, choline, glutamate and glutamine, myo-inositol and total creatine) measured by magnetic resonance spectroscopic imaging, and white matter integrity measured by fractional anisotropy (FA) and mean diffusivity (MD) with diffusion tensor imaging. We used a linear mixed model analysis to compare longitudinal, repeated brain MRI measurements pre-KT, and 3 months and 12 months post-KT, and also compared findings with healthy controls.

Results: 29 ESKD patients and 19 age-matched healthy controls participated in the study. 22 patients underwent post-KT MRI. CBF, which was higher pre-KT than in controls ($p=0.003$), decreased post-KT ($p<0.0001$) to values in controls. KT also normalized concentrations of osmotic neurochemicals choline ($p<0.0001$) and myo-inositol ($p=0.0003$) that were higher pre-KT compared to controls. Post-KT, FA increased ($p=0.001$) and MD decreased ($p=0.0001$).

Conclusions: Brain abnormalities in CKD are reversible and normalize with KT. Further studies are needed to understand the mechanisms underlying these brain abnormalities and to explore interventions to mitigate them even in patients who cannot be transplanted.

Introduction

Chronic kidney disease (CKD) is associated with increased risk of dementia, stroke and mortality.¹ For patients with end stage kidney disease (ESKD), dialysis is a lifesaving procedure, but initiation of dialysis further increases strokes and mortality.² These deleterious clinical findings in CKD can be explained by the structural and physiologic brain abnormalities of increased elevated cerebral blood flow (CBF), altered cerebral neurochemical concentrations and decreased white matter integrity.^{3-11 12-15}

Patients with CKD have elevated cerebral blood flow (CBF),^{7, 8} likely secondary to disrupted cerebral autoregulation from dysfunctional blood brain barrier due to endothelial inflammation.^{16, 17} In addition, hemodialysis causes acute changes in the CBF, associated with ultrafiltration volume and change in hematocrit – major determinants of blood viscosity.¹⁸ These changes in cerebral hemodynamics can contribute to increase in stroke.^{5, 19, 20} Patients with CKD also have dysregulation of cerebral neurochemicals. Cerebral osmolytes such as myo-inositol (ml) and choline containing compounds (Cho) are elevated in CKD.^{4, 9-11} Although causality is unproven, lower estimated glomerular filtration rate (eGFR) is correlated with higher concentrations of some of these osmolytes.²¹ Increase in cerebral osmolytes can alter cerebral osmotic pressure and impair cellular structure and function.²² In addition, patients with CKD have decreased white matter integrity measured by diffusion tensor imaging (DTI),¹²⁻¹⁵ a magnetic resonance imaging (MRI) method to measure the diffusion of water molecules along a nerve tract.²³

Each of these abnormalities is associated with cognitive impairment in the non-CKD population,^{24, 25} and may be responsible for the high prevalence of cognitive impairment in ESKD.²⁶ While many conditions associated with cognitive impairment, such as Alzheimer's disease and traumatic brain injury have irreversible brain abnormalities,²⁷⁻³⁰ due to the unique nature of brain disease in CKD, it is possible that some of these abnormalities are reversible. Since cognition improves after KT,³¹ we hypothesize that brain abnormalities will also improve

with KT. We used KT to comprehensively characterize the structural and physiological brain abnormalities in ESKD and determine their reversibility with KT. We examined CBF, cerebral neurochemical concentrations and white matter integrity longitudinally in patients before and after KT using non-invasive modern MRI techniques. This study builds upon the results of our prior study³¹ and reports a comprehensive evaluation of brain abnormalities pre-to post-KT.

Methods

This is a single center prospective longitudinal observational cohort study on the effect of KT on brain health of ESKD patients on the KT waitlist in comparison to healthy non-CKD controls. The study was approved by the institutional review board and is registered in the US National Library of Medicine, www.clinicaltrials.gov (NCT01883349). Patients waitlisted for KT were enrolled and followed for 12 months post-KT. Brain MRI was performed at baseline, three months and 12 months post-KT. If patients did not receive KT within one year of the baseline visit, a second pre-KT brain MRI was performed to keep the time period between the last pre-KT MRI and KT to less than one year. Controls underwent brain MRI once.

Participants

Adult participants between the ages of 30 and 70 who were listed for KT and expected to receive a KT within a year were enrolled. These included patients scheduled for a living donor KT and patients waitlisted for at least two years. Exclusion criteria included multi-organ listing, claustrophobia, MRI contraindications, recent stroke, uncontrolled psychosis, active seizure disorder, or current use of antipsychotics or anti-epileptics. Controls were age matched healthy persons without CKD or stroke and without contraindications to MRI. All participants signed informed consent prior to initiating study procedures.

Demographics and clinical data

Demographic and clinical data were obtained from patients' medical records and interviews.

Demographic data included age, race, sex and education. Clinical data included assessment of comorbidities, specifically history of coronary artery disease (defined as history of myocardial infarction, coronary angioplasty or coronary artery bypass grafting), diabetes (defined as past or current use of oral hypoglycemics or insulin), hypertension (defined as past or current use of antihypertensives), stroke, depression, smoking (in the last 100 days), use of anticoagulants, atrial fibrillation, primary cause of ESKD and dialysis modality. The type of KT, time on dialysis before KT, kidney function at the time of KT for pre-emptive KTs, induction, panel reactive antibody, delayed graft function and episodes of rejection were also recorded for patients who received a KT during the study period.

Blood pressure, heart rate, and body mass index were also measured. At each visit, laboratory results including hemoglobin, serum creatinine, and tacrolimus levels were recorded from the latest values within the last three months. Serum hemoglobin and creatinine for controls were obtained from their primary care provider or tested specifically for the study to avoid enrollment of controls with undiagnosed CKD. Controls with estimated glomerular filtration rate of less than 60ml/min/1.73m² were excluded from the study.

MRI data acquisition

All MRI scans were performed using a 3 Tesla whole body scanner with a 20-channel head/neck receiver coil (Siemens Skyra, Erlangen, Germany). Modalities captured are described below. Acquisition parameters for each modality were designed to collect data from the whole brain, while maintaining good data quality, high signal to noise ratio, and acceptable spatial resolution.

CBF: CBF was measured using a pulsed arterial spin labeling (ASL) sequence optimized to measure blood flow in gray matter (repetition time/echo time (TR/TE) = 2500/12 ms, field of view

(FOV) = 256 x 256 mm², flip angle = 90 deg, matrix = 64 x 64, slice thickness/gap = 8.0/2.0 mm, voxel in-plane resolution = 4 x 4 mm², 9 axial slices) acquiring 115 pairs of alternating labeled and unlabeled images.^{32, 33} The label offset was set to the distance between magnet isocenter and the junction of the cavernous and cerebral portions of the internal carotid arteries. However, in a subset of sessions, images were acquired so that the superior slice was at the vertex of the brain. We accounted for this variance by including slice position (upper or lower) as a covariate in the statistical analysis.

Cerebral neurochemicals: Neurochemical concentrations were measured with magnetic resonance spectroscopic imaging (MRSI) using a multi-voxel point resolved spectroscopy (PRESS) localized sequence (TR/TE = 1500/30 ms, FOV = 160 x 160 mm², area of interest = 80 x 80 mm², matrix = 16 x 16, final matrix size after 2x zero padding = 32 x 32, elliptical sampling, slice thickness = 10 mm, voxel in-plane resolution = 10 x 10 mm²).^{34, 35} MRSI data were acquired from a fronto-parietal slab placed superior to the corpus callosum and parallel to the anterior commissure-posterior commissure plane, which was positioned to cover the largest two-dimensional area of brain possible. The MRSI slab was carefully placed based on anatomical features in the mid-sagittal T₁-weighted anatomic image to ensure that data were collected from the same anatomic location across participants at repeated time points. B₀ shimming was performed using a vendor-provided field mapping technique.

White matter integrity: White matter integrity was measured by diffusion tensor imaging (DTI).^{36, 37} Data from the whole brain were collected using a double-refocused spin echo sequence optimized to capture major white matter tracts (TR/TE = 10,000/90 ms, FOV 300 × 300 mm, flip angle = 90 deg, matrix = 128 × 128, slice thickness = 2 mm, voxel in-plane resolution = 2.34 x 2.34 mm, 75 axial slices). The diffusion gradients were applied along 64 directions (diffusion gradient pulse δ = 14 ms, diffusion application time Δ = 53 ms, b value = 1,000 s/mm²).

T_1 and T_2^* : T_1 - and T_2^* -weighted anatomic images were also collected and used to align the CBF, MRSI, and DTI data, and for normalization of the regional atlas masks. T_1 -weighted images were acquired with a 3D magnetization-prepared rapid acquisition gradient echo (MPRAGE) sequence (TR/TE = 2300/2.98 ms, FOV = 240 x 256 mm, flip angle = 9 deg, matrix = 240 x 256, slice thickness = 1.2 mm, voxel in-plane resolution = 1.0 x 1.0 mm, 176 sagittal slices).³⁸ T_2^* -weighted images were utilized as the primary anatomic dataset for DTI alignment procedures. These images were acquired with a 2D fast low-angle shot (FLASH) sequence (TR/TE = 650/20 ms, FOV = 220 X 220 mm, flip angle = 20 deg, matrix = 256 x 256, slice thickness = 4.0 mm, voxel in-plane resolution = 0.86 x 0.86 mm, 44 axial slices).³⁹

MR Data Analysis

CBF: ASL data were processed using the ASLTbx⁴⁰ with SPM12,⁴¹ modified for pulsed ASL. For each session, labeled and unlabeled ASL images were independently motion corrected and then a combined mean image was computed. The mean image was co-registered to match the T_1 -weighted anatomical image. The ASL images were then temporally filtered and spatially smoothed with a 6 mm full-width half-maximum Gaussian kernel. CBF was then estimated by subtraction of labeled and unlabeled mean images, resulting in a mean CBF image (units = ml/min/100mg tissue). The structural correlation based outlier rejection (SCORE) algorithm was used to remove outlier voxels.⁴² The T_1 -weighted scan was then normalized using unified segmentation-normalization (SPM12). In addition to whole gray matter CBF, we also assessed regional CBF. These regions were selected *a priori* based on atlas-based regional parcellations of the whole gray matter area distributed across the entire brain. For regional CBF, we used 14 gray matter regions from the Automated Anatomical Labeling atlas; anterior cingulate cortex, middle frontal gyrus, hippocampus, primary motor cortex, posterior cingulate cortex, precuneus, superior parietal cortex, temporal cortex, thalamus, pallidum, putamen, caudate, frontal cortex,

and parietal cortex.⁴³ Mean CBF was computed in regions of interest created from the intersection of the individual gray matter segmentation (probability > 0.5) performed under the SPM unified segmentation algorithm and regional masks from the Automated Anatomical Labeling atlas. Since calculation of CBF includes the MRI longitudinal relaxation time (T1) of blood as a variable, and T1 of blood varies with hematocrit, the calculation was corrected for hematocrit.⁴⁴

Neurochemicals: MRSI data were analyzed using LCModel⁴⁵ with a numerically simulated basis set for concentrations of N-acetylaspartate (NAA), Cho, glutamate and glutamine (Glx), ml and total creatine (Cr). Metabolite concentrations were extracted from gray matter within the MRSI acquisition slab. Voxels were selected for analysis based on the tissue fraction (gray/white matter) in each voxel using the segmented T₁-weighted images and slice selection profiles of radiofrequency pulses corresponding to the spectroscopic voxels. Voxels were included in the analysis if the tissue fraction was greater than 50% gray matter. Analysis was further limited to the center of the region to capture the best quality data and reduce off-resonance effects from the skull and fat surrounding the head. Final concentrations of neurochemicals were therefore obtained from the central 50 x 50 mm² region of the acquisition slab by averaging concentration values using weighting factors derived from the goodness of LCModel fit.⁴⁶ To correct for the differences in levels of different neurochemicals, we normalized the values within each individual by reporting concentrations for NAA, Cho, ml and Glx as ratios to Cr.⁴⁷

White matter integrity: DTI data were processed using Analysis of Functional NeuroImages (AFNI)⁴⁸ software, and TORTOISE version 3.1.4 DIFF_PREP and DIFF_CALC processing modules. Processing steps included eddy current correction modeled with quadratic functions; motion distortion correction; echo planar imaging distortion correction; Gibbs ringing correction;⁴⁹ and denoising. TORTOISE DIFF_CALC EstimateTensorNLLS was used to fit the

tensors. DIFFCALC GUI version 2.5 running under IDL Virtual Machine was used to compute the eigenvectors, derive the tensors, and save the output metrics.

DTI output metrics included fractional anisotropy (FA), a measurement of whether diffusion is constrained along any axis, indicating the presence of white matter fiber tracts (range 0-1, with 0 indicating equal diffusion in all directions and 1 indicating unidirectional diffusion), and mean diffusivity (MD), which is calculated by dividing the total diffusion for all three eigenvectors at each voxel by three (for the three eigenvectors, units = $10^{-3} \text{ mm}^2/\text{s}^{-1}$). Diffusivity is reduced in constrained areas like dense white matter fiber tract bundles. High MD may indicate more free water or edema in the brain.²³ Mean FA and MD were exported for each participant and session from regional white matter tract masks. We used 11 white matter tracts from the Johns Hopkins University DTI-based white matter atlases; anterior thalamic radiation, cingulum in the cingulate cortex areas, cingulum in the hippocampal area, corticospinal tract, forceps major, forceps minor, inferior fronto-occipital fasciculus, inferior longitudinal fasciculus, superior longitudinal fasciculus, temporal projection of the superior longitudinal fasciculus, and uncinate fasciculus.⁵⁰⁻⁵² A combined All-tract mask was created as the overlap of all regional masks.

Primary and secondary outcomes: Our primary outcomes were the effects of KT on whole brain gray matter CBF, cerebral neurochemicals (NAA/Cr, Cho/Cr, Glx/Cr, and ml/Cr), and DTI-measured whole brain white matter FA and MD. As secondary outcomes, to better understand possible anatomic specificity of changes, we measured regional CBF, FA, and MD in atlas-defined anatomic regions distributed across the entire brain.

Statistical Analysis

Baseline characteristics between patients and controls were analyzed using descriptive statistics. For categorical variables, differences in frequencies were measured using a

nonparametric Fisher exact test. For continuous variables, mean differences were measured using a two sample t-test. Assumptions of normality for the t-test were inspected by the quantile-quantile plot and histogram. For clinical measurements, unadjusted one-way repeated analysis of variance (ANOVA) was used to measure the continuous outcomes between pre- and post-KT patient groups. Residuals were assessed to evaluate the fit of the underlying model assumptions.

Each imaging modality (ASL, MRSI and DTI) was analyzed separately. Imaging data in controls, as well as pre- and post-KT groups were adjusted for covariates of age,⁵³ race,⁵⁴ sex,⁵⁵ and education level^{56, 57} that can confound results. Since the exact time for KT is unpredictable, a linear mixed-model approach was used to account for repeated observations on participants. A linear mixed-model is more flexible than repeated-measures ANOVA; it allows for variability in time between scans, variability in the number of scans per participant, and the inclusion of participants who have missing data at one or more timepoints.^{58, 59} Each participant's individual intercept was estimated in the model using the random intercept term. Age was calculated at every timepoint in order to both control for the effect of age and function as the time variable. All available imaging data were included in the model to detect any group differences between pre-KT, post-KT, and controls. The pre-KT group includes both pre-KT scans, if available; the post-KT group includes both the 3 month and 12 month post-KT scans, if available. The effect of group (control, pre-KT, post-KT) and covariates (age, race, sex, and education level) were included as fixed effects. Residual plots were assessed to evaluate the model fit. We performed pairwise testing of the three groups, using F- and t-tests as appropriate. We constructed scatter plots mapping each participant's observed measures over time (chronological age), showing both the overall change with aging and the effect of KT. Kidney function (eGFR and serum creatinine) was correlated with post-KT CBF using Pearson's correlation. As a test for whether there would be any change associated with time alone, for those patients who had repeated pre-KT MRI, the pre-KT scans were compared using Wilcoxon nonparametric signed rank test.

Results with $p < 0.05$ were considered statistically significant. All statistical analyses were performed using R Studio (Version 3.6.3) and SAS (Version 9.4, The SAS institute, Cary, NC).

Results

Demographic and Clinical Comparisons

A total of 48 participants, 29 patients and 19 controls were enrolled (**Table 1**). Of the 29 patients, 23 received a KT. 22 completed the 3 month post-KT MRI and 18 completed the 12 month post-KT MRI. Four of the 29 patients were not transplanted within one year and per study protocol, underwent repeated baseline MRI at one year after enrollment. Patients and controls had no differences in age, race, sex or education (all $p > 0.10$) (**Table 1**). The mean serum creatinine and eGFR for controls were 0.85 ± 0.13 mg/dl and 92.8 ± 13.5 ml/min respectively. ESKD patients had a greater incidence of diabetes ($p = 0.03$) and hypertension ($p < 0.0001$) compared to controls. The most common causes of ESKD were diabetes (21%) and autosomal dominant polycystic kidney disease (28%). Six patients had not initiated dialysis at baseline. Clinical characteristics pre- and post-KT are summarized in **Table 2**. Hematocrit and serum calcium increased and serum bicarbonate decreased after KT. Other parameters such as blood pressure, heart rate, and body mass index did not change with KT (all $p > 0.10$) (**Table 2**).

All transplanted patients received induction and maintenance immunosuppression per institutional protocol. **Supplementary Table 1** describes the clinical characteristics of the 22 patients who had a post-KT MRI. Per institutional policy, ABO-incompatible KTs were not performed at our center. Induction immunosuppression consisted of either thymoglobulin or basiliximab (depending on immunological risk of the patient), steroids and a mycophenolate compound. A calcineurin inhibitor (tacrolimus) was started 24 hours after the surgery. Maintenance immunosuppression consisted of a mycophenolate compound and tacrolimus with or without low dose steroids. Post-KT, all patients were on tacrolimus and had a functional graft with a mean serum creatinine of 1.4 ± 0.5 mg/dl (**Table 2**).

Cerebral blood flow

Table 3 shows the comparisons of adjusted ASL-measured CBF between different groups over the total gray matter and in specific anatomic regions within the total gray matter mask. CBF in the total gray matter was higher in pre-KT ESKD patients compared to controls ($p=0.003$) (**Table 3 and Figure 1**) and normalized post-KT to values observed in controls. **Figure 1** shows data for individual participants at pre- and post-KT for comparison. Normalization of CBF post-KT did not correlate with eGFR ($r=0.16$, $p=0.47$) or serum creatinine ($r=-0.29$, $p=0.19$) (**Supplementary Figure 1**). When CBF was analyzed regionally, the decrease in CBF with KT was consistent across all brain regions (**Table 3**).

Brain neurochemicals

Table 4 shows the group comparisons of different neurochemicals measured with MRSI in the in our adjusted linear mixed model. **Figure 2** shows data for individual patients at different time points in the study. Of the four neurochemicals that were analyzed, the Cho/Cr ($p=0.001$) and ml/Cr ($p=0.0001$) were higher in pre-KT patients compared to controls and normalized post-KT. NAA/Cr and Glx/Cr were not different between the pre-KT patients and controls and did not change post-KT.

White matter integrity

Table 5 and Figure 3 show adjusted group comparisons of FA and MD for all tracts and for each of the regional tracts. FA increased pre- to post-KT ($p=0.001$). Neither pre- ($p=0.23$) nor post-KT ($p=0.72$) FA was different from controls. MD decreased post-KT ($p=0.0001$). Similar to FA, neither pre-KT ($p=0.33$) nor post-KT ($p=0.89$) MD was different from controls.

Brain changes without KT

Out of the 29 ESKD patients in the study, four patients had a second pre-KT MRI while awaiting KT. There was no change in CBF, cerebral neurochemicals, FA or MD over one year in these patients (all $p > 0.10$) (**Supplementary Table 2**).

Discussion

In this study we found that structural and physiologic brain abnormalities in ESKD reversed post-KT. CBF, which was elevated pre-KT, decreased post-KT to levels in controls, globally as well as in all anatomic regions of gray matter analyzed. Cho/Cr and ml/Cr which were also elevated pre-KT normalized post-KT. Finally, white matter integrity also normalized with increase in FA and decrease in MD post-KT. We also noted the expected age-related changes in brain measurements that were controlled for in our linear mixed model.

The reversibility of brain abnormalities in CKD has important mechanistic and therapeutic implications. Potential reversibility underscores the need to develop improved management strategies other than KT for patients who cannot be transplanted. Better dialysis techniques that include targeting dialysis related ischemia to reduce metabolic derangements could help prevent and perhaps mitigate some of these abnormalities. Preservation of residual renal function to retain tubular secretion may also positively impact these brain abnormalities. The overarching impact of our observations would be to identify patients with reversible vs. irreversible brain abnormalities and to devise strategies to reverse brain abnormalities with the goal of improving cognition. Cognitive impairment affects eligibility for KT.⁶⁰ However, given that cognitive impairment and brain abnormalities will improve with KT, more of these patients who are currently rejected for KT may be able to receive a KT.

Elevated CBF seen in our pre-KT patients is consistent with other studies in adult^{8, 17} and pediatric⁶¹ patients with CKD. Disruption of cerebral autoregulation due to inflammation and endothelial dysfunction affecting the blood brain barrier may play a role.^{16, 17} Alternatively,

elevated CBF could be secondary to increased metabolic demand. Our results that CBF decreased pre- to post-KT is consistent with prior cross-sectional⁶² and longitudinal studies.⁶³ Some other studies found CBF to be decreased in CKD^{64, 65} likely due to differences in the methodology of assessing CBF. ASL has the advantage of repeatability and ability to quantify global and regional CBF.⁶⁶ Since hemodialysis preferentially affects the watershed areas of the brain,⁶⁷ we also explored regional changes in the brain in addition to global changes. All regions showed a decreasing trend in CBF (**Table 3**), pointing to systemic etiologies such as reduced inflammation and improvement of cerebral autoregulation. It is also possible that CBF decreased due to the vasoconstrictive effects of calcineurin inhibitors. Distinct from the KT-related change in CBF, we observed an age-related decrease in CBF in all participants, a well-established phenomenon seen in the general population.⁶⁸ Although CBF correlates with eGFR in non-transplanted CKD,⁸ we did not see a strong correlation between CBF and post-KT serum creatinine or eGFR in our study (**Supplementary Figure 1**). This is consistent with other studies in KT where CBF⁶² or cognition⁶⁹ is independent of eGFR. It is possible that the changes in CBF and cognition are not caused directly by reduced eGFR, but by an additional confounding variable such as endothelial inflammation or microvascular disease that influences both eGFR and CBF.

Similar to other published studies, we found that pre-KT patients had higher cerebral Cho/Cr and ml/Cr compared to controls.^{4, 9-11} Both Cho/Cr and ml/Cr decreased post-KT. Cho is a phospholipid cell membrane precursor and represents breakdown products such as phosphocholine, phosphatidylcholine, glycerophosphorylcholine and phosphorylcholine.²² Importantly, Cho is also a precursor of trimethylamine N-oxide, a marker of cardiovascular disease and mortality.^{70, 71} ml, primarily found in glial cells, is involved in the phosphoinositide-mediated signal transduction and is a marker of inflammation or gliosis.²² High plasma ml is also associated with the high prevalence of peripheral polyneuropathy in ESKD.⁷² With their relative small size (molecular weight 105 g/mol and 180 g/mol respectively), both compounds are

readily filtered by the glomeruli and eliminated with tubular secretion.^{73, 74} Both plasma^{72, 75} and intracerebral Cho and ml concentrations are elevated in CKD²¹ and decrease only slightly with dialysis.⁹ Cho and ml are both major cerebral osmolytes and high concentrations can increase osmotic pressure in the brain, cause cellular edema and alter cellular structure and function. Both compounds are transported from the plasma to the brain through the blood brain barrier by diffusion and carrier mediated transporter systems.^{76, 77} Due to the blood brain barrier, changes in plasma concentrations of neurochemicals do not correlate with cerebral concentrations in healthy individuals.⁷⁸ However, with the disruption of the blood brain barrier in CKD, higher serum concentrations could theoretically affect cerebral neurochemical concentrations. Our study indicates normalization of Cho and ml post-KT, perhaps by better elimination with tubular secretion^{73, 74} which cannot be restored with dialysis. Improvement in these neurochemicals after KT could restore cerebral osmotic regulation, lower cellular edema and improve cell function and cognition.

Similar to a prior cross-sectional study,⁹ we did not see any differences in the levels of Glx/Cr and NAA/Cr between controls and pre-KT patients, suggesting that CKD does not impact these neurochemicals as much as Cho and ml. Consistent with this hypothesis, there was no change in Glx/Cr and NAA/Cr pre- to post-KT. Glutamine is mainly found in glia and is a precursor to glutamate,²² the most abundant excitatory neurotransmitter in the neurons. NAA is also an osmolyte located in the cell bodies, axons and dendrites of neurons and is a marker of neuronal number, density and integrity.⁷⁹ NAA/Cr is often reduced in neurodegenerative diseases and may not be affected in CKD.²²

Similar to our prior study,³¹ KT resulted in an increase in FA and a decrease in MD. A recent study demonstrated similar findings.⁶³ These changes in FA and MD indicate decreased free dispersion and greater axial movement of water molecules along the white matter tracts. A decrease in cerebral osmolytes and improvement in cerebral edema as described above can explain these DTI results. Pre-KT, even with maintenance dialysis, the clearance of substances

that are eliminated by tubular secretion is reduced and can result in (often subclinical) cerebral edema. Although we have previously shown that patients on dialysis have lower FA and higher MD compared to healthy controls,⁸⁰ we did not find FA and MD values to be significantly different in pre-KT patients and controls in this study. This could be because of the small sample size and single MRI measurements in controls leading to a larger standard deviation.

The evidence that dialysis has short-term and long-term deleterious effects on brain health is rapidly accumulating.^{4, 5, 9-15, 19, 20} Our MRSI and DTI results indicate normalization of cerebral edema post-KT, a finding that is not observed with dialysis. In fact, cerebral edema increases with longer dialysis vintage and higher ultrafiltration volumes.⁸¹ Similarly, change in CBF with dialysis can be detrimental.² We demonstrate reversibility in abnormalities in CBF, neurochemical concentrations and white matter integrity in ESKD. Based on our study protocol, we repeated pre-KT MRI in patients who did not receive KT within one year. We were able to compare two pre-KT MRIs in these patients and did not observe any change in brain abnormalities. Although we do not have the power to make definite conclusions in this study, our previous work⁸⁰ is consistent with this observation. Normalization of brain abnormalities even after 12 months post-KT indicates that the post-KT changes were not due to acute effects of KT such as steroids, but a phenomenon that persists beyond the immediate post-KT period.

Despite our modest sample size, our longitudinal approach, linear mixed model analysis, and a uniform change in measures among patients strengthen our findings. For example, all patients without exception had a decrease in CBF after KT. Unlike other studies, our CBF calculations were corrected for hematocrit. Hematocrit affects blood viscosity and the T_1 of blood in MRI.⁴⁴ As observed in this study, hematocrit changes following KT. Thus, correction for hematocrit is important for accurate CBF measurements in ESKD. Our models were adjusted for age,⁵³ race,⁵⁴ sex,⁵⁵ and level of education.^{56, 57} Age in particular is associated with changes in brain volume and function, and age-related changes observed over many years could be

larger than changes observed in 12 months post-KT. Another strength was the measurement of regional CBF, FA and MD changes in addition to global changes.

In summary, abnormalities in CBF, neurochemical concentrations and white matter integrity in CKD are normalized with KT. This reversibility in brain abnormalities has important implications in appreciating and managing the risk of dementia and stroke in our CKD population. More studies are needed to understand the mechanisms underlying these brain abnormalities, the role of residual kidney function in preserving brain health on dialysis, and to explore innovations in renal replacement therapies to mitigate these abnormalities even in patients who cannot be transplanted.

Author contributions: A.G., W.M.B., J.M.B. and M.J.S. designed the study. R.J.L., E.D.V., and I.Y.C. analyzed the MRI data. R.N.M., P.S. and J.D.M. did the statistical analysis. A.G. and R.J.L. drafted the manuscript. W.M.B., J.M.B., R.N.M., E.D.V. J.D.M. and M.J.S. reviewed and edited the manuscript. All authors approved the final version of the manuscript.

Acknowledgments: This work was supported by National Institutes of Health (NIH) grant K23 AG055666 (to A.G.), the University of Kansas Medical Center Jared Grantham Kidney Institute Pilot Grant (to A.G.), NIH Clinical and Translational Science Award grant UL1 TR002366 (to the University of Kansas Medical Center), NIH grants P30 AG035982 (to the University of Kansas Alzheimer's Disease Center), P30 DK106912 (to the University of Kansas Medical Center Jared Grantham Kidney Institute), R21 AG061549 (to E.D.V.) and S10 RR29577 (to W.M.B.), and a gift from Forrest and Sally Hoglund (to Hoglund Biomedical Imaging Center).

Disclosures: A.G. has consultancy agreement with Novartis pharmaceuticals, has funding support from Novartis and Veloxis Pharmaceuticals and is on the regional medical advisory board for the National Kidney Foundation. E.D.V. is a stakeholder in a provisional patent for measuring cerebral blood flow. M.J.S. is in the Steering Committee of a trial funded by Akebia, attended an advisory board for Bayer and is a consultant for Cardurian (none are relevant to the current manuscript).

Supplemental material Table of Contents

Supplemental Table 1: Transplantation related clinical characteristics of 22 end stage kidney disease (ESKD) patients who received kidney transplantation (KT).

Supplemental Table 2: Comparison of repeated MRI measurements in pre-KT patients. No changes were observed in one year.

Supplementary Figure 1: Scatterplots representing the Pearson's correlation between **A)** CBF and eGFR, and **B)** CBF and serum creatinine 3 months post-KT. A strong correlation was not detected. CBF: cerebral blood flow, eGFR: estimated glomerular filtration rate, KT: kidney transplantation.

References

1. Murray, AM, Seliger, S, Lakshminarayan, K, Herzog, CA, Solid, CA: Incidence of stroke before and after dialysis initiation in older patients. *J Am Soc Nephrol*, 24: 1166-1173, 2013.
2. Wachterman, MW, O'Hare, AM, Rahman, O-K, Lorenz, KA, Marcantonio, ER, Alicante, GK, Kelley, AS: One-Year Mortality After Dialysis Initiation Among Older Adults. *JAMA Intern Med*, 179: 987-990, 2019.
3. Hsieh, PC, Lin, JH, Lee, CL: Mixing of dissolved organic matter from distinct sources: using fluorescent pyrene as a probe. *J Environ Sci Health A Tox Hazard Subst Environ Eng*, 44: 170-178, 2009.
4. Tryc, AB, Alwan, G, Bokemeyer, M, Goldbecker, A, Hecker, H, Haubitz, M, Weissenborn, K: Cerebral metabolic alterations and cognitive dysfunction in chronic kidney disease. *Nephrol Dial Transplant*, 26: 2635-2641, 2011.
5. Prohovnik, I, Post, J, Uribarri, J, Lee, H, Sandu, O, Langhoff, E: Cerebrovascular effects of hemodialysis in chronic kidney disease. *J Cereb Blood Flow Metab*, 27: 1861-1869, 2007.
6. Drew, DA, Bhadelia, R, Tighiouart, H, Novak, V, Scott, TM, Lou, KV, Shaffi, K, Weiner, DE, Sarnak, MJ: Anatomic brain disease in hemodialysis patients: a cross-sectional study. *Am J Kidney Dis*, 61: 271-278, 2013.
7. Ikram, MA, Vernooij, MW, Hofman, A, Niessen, WJ, van der Lugt, A, Breteler, MM: Kidney function is related to cerebral small vessel disease. *Stroke; a journal of cerebral circulation*, 39: 55-61, 2008.
8. Tamura, MK, Pajewski, NM, Bryan, RN, Weiner, DE, Diamond, M, Van Buren, P, Taylor, A, Beddhu, S, Rosendorff, C, Jahanian, H, Zaharchuk, G, Group, SSR: Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. *Neurology*, 86: 1208-1216, 2016.

9. Michaelis, T, Videen, JS, Linsey, MS, Ross, BD: Dialysis and transplantation affect cerebral abnormalities of end-stage renal disease. *J Magn Reson Imaging*, 6: 341-347, 1996.
10. Geissler, A, Frund, R, Kohler, S, Eichhorn, HM, Kramer, BK, Feuerbach, S: Cerebral metabolite patterns in dialysis patients: evaluation with H-1 MR spectroscopy. *Radiology*, 194: 693-697, 1995.
11. Menon, DK, Sandford, RN, Cassidy, MJ, Bell, JD, Baudouin, CJ, Sargentoni, J: Proton magnetic resonance spectroscopy in chronic renal failure. *Lancet*, 337: 244-245, 1991.
12. Hsieh, TJ, Chang, JM, Chuang, HY, Ko, CH, Hsieh, ML, Liu, GC, Hsu, JS: End-stage renal disease: in vivo diffusion-tensor imaging of silent white matter damage. *Radiology*, 252: 518-525, 2009.
13. Eldehni, MT, Odudu, A, McIntyre, CW: Randomized clinical trial of dialysate cooling and effects on brain white matter. *J Am Soc Nephrol*, 26: 957-965, 2015.
14. Chou, MC, Hsieh, TJ, Lin, YL, Hsieh, YT, Li, WZ, Chang, JM, Ko, CH, Kao, EF, Jaw, TS, Liu, GC: Widespread white matter alterations in patients with end-stage renal disease: a voxelwise diffusion tensor imaging study. *AJNR Am J Neuroradiol*, 34: 1945-1951, 2013.
15. Zhang, R, Liu, K, Yang, L, Zhou, T, Qian, S, Li, B, Peng, Z, Li, M, Sang, S, Jiang, Q, Sun, G: Reduced white matter integrity and cognitive deficits in maintenance hemodialysis ESRD patients: a diffusion-tensor study. *Eur Radiol*, 25: 661-668, 2015.
16. Lau, WL, Nunes, ACF, Vasilevko, V, Florioli, D, Lertpanit, L, Savoj, J, Bangash, M, Yao, Z, Shah, K, Naqvi, S, Paganini-Hill, A, Vaziri, ND, Cribbs, DH, Fisher, M: Chronic Kidney Disease Increases Cerebral Microbleeds in Mouse and Man. *Translational Stroke Research*, 11: 122-134, 2020.
17. Lau, WL, Huisa, BN, Fisher, M: The Cerebrovascular-Chronic Kidney Disease Connection: Perspectives and Mechanisms. *Transl Stroke Res*, 8: 67-76, 2017.

18. Hata, R, Matsumoto, M, Handa, N, Terakawa, H, Sugitani, Y, Kamada, T: Effects of hemodialysis on cerebral circulation evaluated by transcranial Doppler ultrasonography. *Stroke*, 25: 408-412, 2018.
19. Polinder-Bos, HA, Garcia, DV, Kuipers, J, Elting, JWJ, Aries, MJH, Krijnen, WP, Groen, H, Willemsen, ATM, van Laar, PJ, Strijkert, F, Luurtsema, G, Slart, R, Westerhuis, R, Gansevoort, RT, Gaillard, C, Franssen, CFM: Hemodialysis Induces an Acute Decline in Cerebral Blood Flow in Elderly Patients. *J Am Soc Nephrol*, 29: 1317-1325, 2018.
20. Findlay, MD, Dawson, J, Dickie, DA, Forbes, KP, McGlynn, D, Quinn, T, Mark, PB: Investigating the Relationship between Cerebral Blood Flow and Cognitive Function in Hemodialysis Patients. *J Am Soc Nephrol*, 30: 147-158, 2019.
21. Sasaki, O, Hattori, N, Nakahama, H, Inoue, N, Nakamura, S, Inenaga, T, Kohno, S, Sawada, T, Kawano, Y: Positive correlations between cerebral choline and renal dysfunction in chronic renal failure. *Neuroradiology*, 48: 300-306, 2006.
22. Su, L, Blamire, AM, Watson, R, He, J, Hayes, L, O'Brien, JT: Whole-brain patterns of ¹H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies. *Transl Psychiatry*, 6: e877-e877, 2016.
23. Sotak, CH: The role of diffusion tensor imaging in the evaluation of ischemic brain injury - a review. *NMR Biomed*, 15: 561-569, 2002.
24. Mayo, CD, Garcia-Barrera, MA, Mazerolle, EL, Ritchie, LJ, Fisk, JD, Gawryluk, JR, Alzheimer's Disease Neuroimaging, I: Relationship Between DTI Metrics and Cognitive Function in Alzheimer's Disease. *Frontiers in aging neuroscience*, 10: 436-436, 2019.
25. Ferguson, KJ, MacLulich, AM, Marshall, I, Deary, IJ, Starr, JM, Seckl, JR, Wardlaw, JM: Magnetic resonance spectroscopy and cognitive function in healthy elderly men. *Brain*, 125: 2743-2749, 2002.

26. Murray, AM, Tupper, DE, Knopman, DS, Gilbertson, DT, Pederson, SL, Li, S, Smith, GE, Hochhalter, AK, Collins, AJ, Kane, RL: Cognitive impairment in hemodialysis patients is common. *Neurology*, 67: 216-223, 2006.
27. Friedman, SD, Brooks, WM, Jung, RE, Hart, BL, Yeo, RA: Proton MR spectroscopic findings correspond to neuropsychological function in traumatic brain injury. *AJNR Am J Neuroradiol*, 19: 1879-1885, 1998.
28. Kraus, MF, Susmaras, T, Caughlin, BP, Walker, CJ, Sweeney, JA, Little, DM: White matter integrity and cognition in chronic traumatic brain injury: a diffusion tensor imaging study. *Brain : a journal of neurology*, 130: 2508-2519, 2007.
29. Mrak, RE, Griffin, ST, Graham, DI: Aging-associated changes in human brain. *J Neuropathol Exp Neurol*, 56: 1269-1275, 1997.
30. De Deyn, PP, Goeman, J, Engelborghs, S, Hauben, U, D'Hooge, R, Baro, F, Pickut, BA: From neuronal and vascular impairment to dementia. *Pharmacopsychiatry*, 32 Suppl 1: 17-24, 1999.
31. Gupta, A, Lepping, RJ, Yu, AS, Perea, RD, Honea, RA, Johnson, DK, Brooks, WM, Burns, JM: Cognitive Function and White Matter Changes Associated with Renal Transplantation. *Am J Nephrol*, 43: 50-57, 2016.
32. Wong, EC: An introduction to ASL labeling techniques. *J Magn Reson Imaging*, 40: 1-10, 2014.
33. Haller, S, Zaharchuk, G, Thomas, DL, Lovblad, KO, Barkhof, F, Golay, X: Arterial Spin Labeling Perfusion of the Brain: Emerging Clinical Applications. *Radiology*, 281: 337-356, 2016.
34. Kim, DH, Henry, R, Spielman, DM: Fast multivoxel two-dimensional spectroscopic imaging at 3 T. *Magn Reson Imaging*, 25: 1155-1161, 2007.
35. Serkova, NJ, Brown, MS: Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers. *Bioanalysis*, 4: 321-341, 2012.

36. Pierpaoli, C, Jezzard, P, Basser, PJ, Barnett, A, Di Chiro, G: Diffusion tensor MR imaging of the human brain. *Radiology*, 201: 637-648, 1996.
37. Peled, S, Gudbjartsson, H, Westin, CF, Kikinis, R, Jolesz, FA: Magnetic resonance imaging shows orientation and asymmetry of white matter fiber tracts. *Brain research*, 780: 27-33, 1998.
38. Shah, M, Ross, JS, Tkach, J, Modic, MT: 3D MPRAGE evaluation of the internal auditory canals. *J Comput Assist Tomogr*, 17: 442-445, 1993.
39. Frahm, J, Haase, A, Matthaei, D: Rapid three-dimensional MR imaging using the FLASH technique. *J Comput Assist Tomogr*, 10: 363-368, 1986.
40. Wang, Z, Aguirre, GK, Rao, H, Wang, J, Fernandez-Seara, MA, Childress, AR, Detre, JA: Empirical optimization of ASL data analysis using an ASL data processing toolbox: ASLtbx. *Magn Reson Imaging*, 26: 261-269, 2008.
41. Friston, KJ, Ashburner, J: SPM12 [computer program]. London, UK, Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology, 2020.
42. Dolui, S, Wang, Z, Shinohara, RT, Wolk, DA, Detre, JA, Alzheimer's Disease Neuroimaging, I: Structural Correlation-based Outlier Rejection (SCORE) algorithm for arterial spin labeling time series. *J Magn Reson Imaging*, 45: 1786-1797, 2017.
43. Tzourio-Mazoyer, N, Landeau, B, Papathanassiou, D, Crivello, F, Etard, O, Delcroix, N, Mazoyer, B, Joliot, M: Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*, 15: 273-289, 2002.
44. Lu, H, Clingman, C, Golay, X, van Zijl, PC: Determining the longitudinal relaxation time (T1) of blood at 3.0 Tesla. *Magn Reson Med*, 52: 679-682, 2004.
45. Provencher, SW: Automatic quantitation of localized in vivo ¹H spectra with LCModel. *NMR Biomed*, 14: 260-264, 2001.

46. Harris, JL, Yeh, HW, Swerdlow, RH, Choi, IY, Lee, P, Brooks, WM: High-field proton magnetic resonance spectroscopy reveals metabolic effects of normal brain aging. *Neurobiology of aging*, 35: 1686-1694, 2014.
47. Pouwels, PJ, Kruse, B, Korenke, GC, Mao, X, Hanefeld, FA, Frahm, J: Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. *Neuropediatrics*, 29: 254-264, 1998.
48. Cox, RW: AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. *Comput Biomed Res*, 29: 162-173, 1996.
49. Kellner, E, Dhital, B, Kiselev, VG, Reiser, M: Gibbs-ringing artifact removal based on local subvoxel-shifts. *Magn Reson Med*, 76: 1574-1581, 2016.
50. Mori, S, Wakana, S, van Zijl, PCM, Nagae-Poetscher, LM: *MRI Atlas of Human White Matter*, Amsterdam, The Netherlands, Elsevier, 2005.
51. Wakana, S, Caprihan, A, Panzenboeck, MM, Fallon, JH, Perry, M, Gollub, RL, Hua, K, Zhang, J, Jiang, H, Dubey, P, Blitz, A, van Zijl, P, Mori, S: Reproducibility of quantitative tractography methods applied to cerebral white matter. *Neuroimage*, 36: 630-644, 2007.
52. Hua, K, Zhang, J, Wakana, S, Jiang, H, Li, X, Reich, DS, Calabresi, PA, Pekar, JJ, van Zijl, PC, Mori, S: Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract-specific quantification. *Neuroimage*, 39: 336-347, 2008.
53. Amen, DG, Egan, S, Meysami, S, Raji, CA, George, N: Patterns of Regional Cerebral Blood Flow as a Function of Age Throughout the Lifespan. *Journal of Alzheimer's disease : JAD*, 65: 1087-1092, 2018.
54. Ku, E, Yang, W, McCulloch, CE, Feldman, HI, Go, AS, Lash, J, Bansal, N, He, J, Horwitz, E, Ricardo, AC, Shafi, T, Sondheim, J, Townsend, RR, Waikar, SS, Hsu, CY, Investigators, CS: Race and Mortality in CKD and Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. *Am J Kidney Dis*, 75: 394-403, 2020.

55. Nitsch, D, Grams, M, Sang, Y, Black, C, Cirillo, M, Djurdjev, O, Iseki, K, Jassal, SK, Kimm, H, Kronenberg, F, Oien, CM, Levey, AS, Levin, A, Woodward, M, Hemmelgarn, BR, Chronic Kidney Disease Prognosis, C: Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. *BMJ*, 346: f324, 2013.
56. Mortel, KF, Meyer, JS, Herod, B, Thornby, J: Education and occupation as risk factors for dementias of the Alzheimer and ischemic vascular types. *Dementia*, 6: 55-62, 1995.
57. Ostojic, J, Kozic, D, Ostojic, SM: N-Acetylaspartate-to-creatine ratio in twelve brain locations among healthy men and women with different levels of education. *Neuroscience letters*, 692: 23-26, 2019.
58. Cnaan, A, Laird, NM, Slasor, P: Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. *Stat Med*, 16: 2349-2380, 1997.
59. Gueorguieva, R, Krystal, JH: Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. *Arch Gen Psychiatry*, 61: 310-317, 2004.
60. Gupta, A, Montgomery, RN, Bedros, V, Lesko, J, Mahnken, JD, Chakraborty, S, Drew, D, Klein, JA, Thomas, TS, Ilahe, A, Budhiraja, P, Brooks, WM, Schmitt, TM, Samak, MJ, Burns, JM, Cibrik, DM: Subclinical Cognitive Impairment and Listing for Kidney Transplantation. *Clinical Journal of the American Society of Nephrology*, 14: 567, 2019.
61. Liu, H-S, Hartung, EA, Jawad, AF, Ware, JB, Laney, N, Port, AM, Gur, RC, Hooper, SR, Radcliffe, J, Furth, SL, Detre, JA: Regional Cerebral Blood Flow in Children and Young Adults with Chronic Kidney Disease. *Radiology*, 288: 849-858, 2018.
62. Kamano, C, Komaba, Y, Sakayori, O, Iino, Y, Katayama, Y: Decreased cerebral blood flow in renal transplant recipients. *Internal medicine (Tokyo, Japan)*, 41: 677-683, 2002.
63. Sandwijk, MSv, Berge, IJMt, Caan, MWA, Düring, M, Gool, WAv, Majoie, CBLM, Mutsaerts, H-JMM, Schmand, BA, Schranter, A, Sonneveld, LMJd, Bemelman, FJ: Cognitive

- Improvement After Kidney Transplantation Is Associated With Structural and Functional Changes on MRI. *Transplant Direct*, 6: e531, 2020.
64. Sedaghat, S, Vernooij, MW, Loehrer, E, Mattace-Raso, FU, Hofman, A, van der Lugt, A, Franco, OH, Dehghan, A, Ikram, MA: Kidney Function and Cerebral Blood Flow: The Rotterdam Study. *J Am Soc Nephrol*, 27: 715-721, 2016.
 65. Fazekas, G, Fazekas, F, Schmidt, R, Flook, E, Valetitsch, H, Kapeller, P, Krejs, GJ: Pattern of cerebral blood flow and cognition in patients undergoing chronic haemodialysis treatment. *Nucl Med Commun*, 17: 603-608, 1996.
 66. Wintermark, M, Sesay, M, Barbier, E, Borbely, K, Dillon, WP, Eastwood, JD, Glenn, TC, Grandin, CB, Pedraza, S, Soustiel, JF, Nariai, T, Zaharchuk, G, Caille, JM, Dousset, V, Yonas, H: Comparative overview of brain perfusion imaging techniques. *J Neuroradiol*, 32: 294-314, 2005.
 67. Davenport, A, Buscombe, JR: Watershed cerebral infarction in a hemodialysis patient. *Kidney Int*, 77: 1140, 2010.
 68. Gur, RC, Gur, RE, Obrist, WD, Skolnick, BE, Reivich, M: Age and Regional Cerebral Blood Flow at Rest and During Cognitive Activity. *Arch Gen Psychiatry*, 44: 617-621, 1987.
 69. Gupta, A, Mahnken, JD, Johnson, DK, Thomas, TS, Subramaniam, D, Polshak, T, Gani, I, John Chen, G, Burns, JM, Sarnak, MJ: Prevalence and correlates of cognitive impairment in kidney transplant recipients. *BMC Nephrol*, 18: 158, 2017.
 70. Stubbs, JR, House, JA, Ocque, AJ, Zhang, S, Johnson, C, Kimber, C, Schmidt, K, Gupta, A, Wetmore, JB, Nolin, TD, Spertus, JA, Yu, AS: Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. *Journal of the American Society of Nephrology*, 27: 305-313, 2016.
 71. Heianza, Y, Ma, W, Manson, JE, Rexrode, KM, Qi, L: Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and

- Meta-Analysis of Prospective Studies. *Journal of the American Heart Association*, 6, 2017.
72. Clements, RS, Jr., DeJesus, PV, Jr., Winegrad, AI: Raised plasma-myoinositol levels in uraemia and experimental neuropathy. *Lancet (London, England)*, 1: 1137-1141, 1973.
 73. Acara, M, Roch-Ramel, F, Rennick, B: Bidirectional renal tubular transport of free choline: a micropuncture study. *Am J Physiol*, 236: F112-118, 1979.
 74. Silbernagl, S, Volker, K, Dantzler, WH: Tubular reabsorption of myo-inositol vs. that of D-glucose in rat kidney in vivo et situ. *Am J Physiol Renal Physiol*, 284: F1181-1189, 2003.
 75. Melmed, S, Lewin, LM, Bank, H: Myo-inositol clearance in renal failure and in patients with normal kidney function. *The American journal of the medical sciences*, 274: 55-59, 1977.
 76. Spector, R: Myo-inositol transport through the blood-brain barrier. *Neurochem Res*, 13: 785-787, 1988.
 77. Allen, DD, Lockman, PR: The blood-brain barrier choline transporter as a brain drug delivery vector. *Life Sci*, 73: 1609-1615, 2003.
 78. Takado, Y, Sato, N, Kanbe, Y, Tomiyasu, M, Xin, L, Near, J, Yoshikawa, K, Sahara, N, Higashi, T, Suhara, T, Higuchi, M, Obata, T: Association between Brain and Plasma Glutamine Levels in Healthy Young Subjects Investigated by MRS and LC/MS. *Nutrients*, 11, 2019.
 79. Benarroch, EE: N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. *Neurology*, 70: 1353-1357, 2008.
 80. Drew, DA, Koo, B-B, Bhadelia, R, Weiner, DE, Duncan, S, la Garza, MM-D, Gupta, A, Tighiouart, H, Scott, T, Sarnak, MJ: White matter damage in maintenance hemodialysis patients: a diffusion tensor imaging study. *BMC nephrology*, 18: 213-213, 2017.
 81. Reetz, K, Abbas, Z, Costa, AS, Gras, V, Tiffin-Richards, F, Mirzazade, S, Holschbach, B, Frank, RD, Vassiliadou, A, Krüger, T, Eitner, F, Gross, T, Schulz, JB, Floege, J, Shah,

NJ: Increased Cerebral Water Content in Hemodialysis Patients. *PloS one*, 10: e0122188, 2015.

Tables

Table 1: Baseline demographics and clinical characteristics of study participants.

	Controls (n=19)	ESKD patients (n=29)	p-value
Age years, mean $\pm$ SD	48.78 $\pm$ 8.38	53.43 $\pm$ 11.38	0.11
Race, n (%)			0.65
White	17 (89.5)	25 (86.2)	
Black	0 (0.0)	2 (6.9)	
Other	2 (10.5)	2 (6.9)	
Sex n (%)			0.23
Males	9 (47.4)	20 (69.0)	
Females	10 (52.6)	9 (31.0)	
Education, n (%)			0.32
High school diploma	1 (5.3)	5 (17.2)	
Some college	3 (15.8)	9 (31.0)	
4-year college degree	7 (36.8)	8 (27.6)	
Graduate school	8 (42.1)	7 (24.1)	
Comorbid conditions, n (%)			
Coronary artery disease	0 (0.0)	3 (10.3)	0.27
Diabetes	0 (0.0)	7 (24.1)	0.03
Hypertension	5 (26.3)	25 (86.2)	<0.0001
Stroke	0 (0.0)	1 (3.5)	0.99
Depression	2 (10.5)	7 (24.1)	0.29
Smoking	6 (31.6)	9 (31.0)	0.99
On anticoagulants, n (%)		2 (6.9)	
Atrial fibrillation, n (%)		3 (10.3)	
Cause of ESKD, n (%)	NA		NA
Diabetes		6 (20.7)	
Hypertension		3 (10.3)	
ADPKD		8 (27.6)	
Other		12 (41.4)	
Dialysis modality, n (%)	NA		NA
In center hemodialysis		11 (37.9)	
Home hemodialysis		3 (10.4)	
Peritoneal dialysis		9 (31.0)	
Not on dialysis		6 (20.7)	

ESKD: end-stage kidney disease, ADPKD: autosomal dominant polycystic kidney disease. Continuous values are presented as mean $\pm$ standard deviation (SD), p values represent unadjusted two sample t-test. Categorical variables are presented as frequency (percentage), p value represents unadjusted nonparametric Fisher exact test.

Table 2: Pre- to post-KT changes in clinical measures.

	1-year pre-KT (n=4) (mean ± SD)	Pre-KT (n=29) (mean ± SD)	3 months post-KT (n=22) (mean ± SD)	12 months post-KT (n=18) (mean ± SD)	p-value
Hematocrit	33.9 ± 4.6	33.3 ± 4.1	39.7 ± 4.2	43.6 ± 4.2	<0.0001
Serum calcium (mg/dl)	9.5 ± 0.4	9.5 ± 0.5	9.8 ± 0.5	9.7 ± 0.4	0.004
Serum bicarbonate (mEq/L)	23.3 ± 2.2	25.5 ± 3.5	24.0 ± 1.8	23.3 ± 2.7	0.02
Serum Creatinine (mg/dl)	NA	NA	1.4 ± 0.5	1.3 ± 0.5	NA
eGFR (mL/min/1.73m²)	NA	NA	55.4 ± 13.7	55.7 ± 13.8	NA
Tacrolimus level (ng/mL)	NA	NA	11.4 ± 12.4	7.8 ± 3.2	NA
SBP (mm Hg)	114.5 ± 7.0	141.9 ± 16.5	137.5 ± 17.8	138.8 ± 15.1	0.69
DBP (mm Hg)	62.3 ± 10.5	79.2 ± 10.3	77.7 ± 10.1	77.3 ± 13.2	0.98
HR (beats/min)	75.5 ± 7.7	75.9 ± 14.5	75.4 ± 10.8	74.4 ± 16.1	0.67
BMI (kg/m²)	31.0 ± 3.8	30.0 ± 4.8	30.0 ± 5.1	35.0 ± 13.2	0.20

KT: kidney transplantation, eGFR: estimated glomerular filtration rate, SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate, BMI: body mass index.

All measures are presented as mean ± standard deviation (SD).

p values represent unadjusted one-way repeated measures ANOVA for pre-to post-transplant comparison.

Table 3: Overall gray matter and regional comparisons of cerebral blood flow in pre-KT ESKD patients, post-KT ESKD patients and controls.

	p-value ^a	Pairwise comparisons Estimated difference (p-value) ^b		
		Change pre- to post-KT	Pre-KT vs. control	Post-KT vs. control
Total gray matter	<0.0001	-7.24 (<0.0001)	7.91 (0.003)	0.67 (0.78)
Regions analyzed				
ACC	0.07	-5.40 (0.02)	5.21 (0.20)	-0.19 (0.96)
Frontal Mid	0.008	-7.37 (0.002)	7.00 (0.05)	-0.37 (0.91)
Hippocampus	<0.0001	-8.67 (<0.0001)	10.89 (0.002)	2.21 (0.46)
M1	0.002	-6.30 (0.001)	7.58 (0.02)	1.28 (0.65)
PCC	0.0004	-12.17 (<0.0001)	9.39 (0.06)	-2.78 (0.54)
Precuneus	0.0001	-10.40 (<0.0001)	9.12 (0.017)	-1.28 (0.71)
Superior Parietal	0.03	-6.77 (0.01)	4.45 (0.24)	-2.32 (0.49)
Temporal	0.001	-5.84 (0.001)	7.69 (0.01)	1.85 (0.47)
Thalamus	<0.0001	-2.55 (<0.0001)	13.15 (0.01)	0.28 (0.95)
Pallidum	0.03	-6.11 (0.01)	5.77 (0.17)	-0.35 (0.93)
Putamen	0.001	-7.09 (0.001)	8.26 (0.018)	1.17 (0.71)
Caudate	0.008	-7.13 (0.002)	6.63 (0.05)	-0.49 (0.87)
Frontal	0.003	-6.30 (0.001)	7.26 (0.01)	0.96 (0.71)
Parietal	0.0003	-8.36 (<0.0001)	8.85 (0.01)	0.49 (0.87)

KT: kidney transplantation, ACC: anterior cingulate cortex, Frontal Mid: middle frontal gyrus, M1: primary motor cortex, PCC: posterior cingulate cortex.

^a p value for linear mixed model F-test for any group differences between pre-KT, post-KT, and controls, adjusted for age, race, sex, and education level. Pre-KT includes both pre-KT scans, if available; post-KT includes both the 3 month and 12 month post-KT scans, if available. ^b p value for adjusted linear contrast of pairwise estimated group differences t-test. All units are in ml/min/100mg tissue.

Table 4: Comparisons of brain neurochemical concentrations normalized to creatine in pre-KT ESKD patients, post-KT ESKD patients and controls.

Neurochemical analyzed	p-value ^a	Pairwise comparisons Estimated difference (p-value) ^b		
		Change pre- to post-KT	Pre-KT vs. control	Post-KT vs. control
NAA/Cr	0.04	0.02 (0.14)	0.06 (0.08)	0.09 (0.02)
Cho/Cr	<0.0001	-0.006 (<0.0001)	0.04 (0.001)	0.008 (0.47)
Glx/Cr	0.23	0.05 (0.23)	-0.08 (0.10)	-0.04 (0.47)
ml/Cr	<0.0001	-0.06 (0.0003)	0.11 (0.0001)	0.05 (0.05)

KT: kidney transplantation, NAA: N-acetylaspartate, Cr: total creatine, Cho: choline, Glx: glutamate and glutamine, ml: myo-inositol.

^a p value for linear mixed model F-test for any group differences between pre-KT, post-KT, and controls, adjusted for age, race, sex, and education level. Pre-KT includes both pre-KT scans, if available; post-KT includes both the 3 month and 12 month post-KT scans, if available. ^b p value for adjusted linear contrast of pairwise estimated group differences t-test. Units are ratios to creatine.

Table 5: Whole brain and regional comparisons of diffusion metrics fractional anisotropy (FA) and mean diffusivity (MD) in pre-KT ESKD patients, post-KT ESKD patients and controls.

Regions and metrics analyzed	p-value ^a	Pairwise comparisons Estimated difference (p-value) ^b		
		Change pre- to post-KT	Pre-KT vs. control	Post-KT vs. control
All tracts FA	0.003	0.007 (0.001)	-0.010 (0.23)	-0.003 (0.72)
All tracts MD	0.001	-0.022 (0.0001)	0.019 (0.33)	-0.003 (0.89)
Regional FA				
ATR	0.001	0.011 (0.0002)	-0.018 (0.19)	-0.007 (0.63)
CG	0.71	0.004 (0.58)	-0.024 (0.52)	-0.020 (0.59)
CH	0.51	0.109 (0.46)	0.017 (0.52)	0.028 (0.29)
CST	0.06	0.009 (0.02)	-0.001 (0.93)	0.008 (0.50)
FMAJ	0.26	0.006 (0.14)	-0.015 (0.40)	-0.009 (0.62)
FMIN	0.22	0.006 (0.16)	0.008 (0.45)	0.014 (0.19)
IFOF	0.02	0.008 (0.01)	-0.015 (0.20)	-0.007 (0.56)
ILF	0.005	0.009 (0.002)	-0.015 (0.16)	-0.006 (0.58)
SLF	0.23	0.002 (0.54)	-0.015 (0.09)	-0.013 (0.14)
SLFT	0.60	0.002 (0.52)	-0.010 (0.40)	-0.007 (0.52)
UF	0.27	0.011 (0.15)	-0.017 (0.31)	-0.007 (0.70)
Regional MD				
ATR	0.008	-0.367 (0.002)	0.045 (0.47)	0.008 (0.90)
CG	0.0018	-0.016 (0.005)	0.020 (0.25)	0.004 (0.83)
CH	0.33	-0.169 (0.50)	-0.070 (0.25)	-0.087 (0.15)
CST	0.12	-0.011 (0.09)	-0.013 (0.41)	-0.024 (0.14)
FMAJ	0.004	-0.042 (0.002)	0.049 (0.15)	0.007 (0.83)
FMIN	0.08	-0.020 (0.03)	0.002 (0.92)	-0.018 (0.35)
IFOF	0.0003	-0.187 (0.0001)	0.027 (0.11)	0.009 (0.60)
ILF	0.003	-0.006 (0.001)	0.026 (0.35)	0.002 (0.93)
SLF	0.003	-0.012 (0.001)	0.022 (0.13)	0.009 (0.52)
SLFT	0.0003	-0.010 (0.0001)	0.015 (0.12)	0.005 (0.59)
UF	0.33	-0.020 (0.14)	0.009 (0.82)	-0.011 (0.78)

KT: kidney transplantation, FA: fractional anisotropy, MD: mean diffusivity, ATR: anterior thalamic radiation, CG: cingulum in the cingulate cortex area CH: cingulum in the hippocampal area, CST: corticospinal tract, FMAJ: forceps major, FMIN: forceps minor, IFOF: inferior fronto-occipital fasciculus, ILF: inferior longitudinal fasciculus, SLF: superior longitudinal fasciculus, SLFT: temporal projection of the SLF, UF: uncinate fasciculus.

^a p value for linear mixed model F-test for any group differences between pre-KT, post-KT, and controls, adjusted for age, race, sex, and education level. Pre-KT includes both pre-KT scans, if available; post-KT includes both the 3 month and 12 month post-KT scans, if available. ^b p value for adjusted linear contrast of pairwise estimated between group differences t-test. Units are scalar (0-1) for FA and $10^{-3} \text{ mm}^2/\text{sec}^{-1}$ for MD.

Figures

Figure 1: Comparisons of cerebral blood flow in total gray matter in pre-KT patients, post-KT patients and controls. Scatterplot displays individual participant data as a function of age and group (Controls: Black circles, Pre-KT: Red circles, Post-KT, Green circles). Dashed lines represent individual participant trajectory over time. Distance between the solid lines represents the estimated group mean differences for fixed covariate values of race (white), sex (male), education (more than high school), and slice position (upper). The slope of the solid lines represents the overall effect of age. ESKD: end stage kidney disease, KT: kidney transplantation, CBF: cerebral blood flow.

Figure 2: Comparisons of MR spectroscopy imaging measured **A)** NAA/Cr ratio **B)** Cho/Cr ratio **C)** Glx/Cr ratio and **D)** ml/Cr ratio in pre-KT patients, post-KT patients and controls. Scatterplot displays individual participant data as a function of age and group (Controls: Black circles, Pre-KT: Red circles, Post-KT, Green circles). Dashed lines represent individual participant trajectory over time. Distance between the solid lines represents the estimated group mean differences for fixed covariate values of race (white), sex (male), and education (more than high school). The slope of the solid lines represents the overall effect of age. ESKD: end stage kidney disease, KT: kidney transplantation, NAA: N-acetylaspartate, Cr: total creatine, Cho: choline, Glx: glutamate and glutamine, ml: myo-inositol.

Figure 3: Comparisons of diffusion metrics **A)** Fractional anisotropy (FA) and **B)** Mean diffusivity (MD) in whole brain in pre-KT patients, post-KT patients and controls. Scatterplot displays individual participant data as a function of age and group (Controls: Black circles, Pre-KT: Red circles, Post-KT, Green circles). Dashed lines represent individual participant trajectory over time. Distance between the solid lines represents the estimated group mean differences for fixed covariate values of race (white), sex (male), and education (more than high school). The slope of the solid lines represents the overall effect of age. ESKD: end stage kidney disease, KT: kidney transplantation, FA: fractional anisotropy, MD: mean diffusivity.